GLP-1 RAs Show Promising Weight Loss and Safety in Older Adults

The prevalence of obesity in older adults is a significant public health challenge, contributing to numerous comorbidities such as type 2 diabetes, cardiovascular disease, and mobility impairment. While GLP-1 Receptor Agonists (GLP-1 RAs), a class of drugs that mimic natural hormones to regulate appetite and metabolism, have demonstrated substantial efficacy for weight management in younger populations, there remains a paucity of dedicated research and clinical guidance regarding their specific use, efficacy, and safety profiles in the geriatric population.

Across the eight patients, the GLP-1 RA treatment resulted in a mean weight loss of 11.8% from baseline, ranging from 8.5% to 15.2% over the observation period. Mean BMI decreased by 3.9 kg/m², moving from an average of 34.5 kg/m² to 30.6 kg/m², indicating a significant reduction in obesity severity. > The most significant finding was that 75% of patients achieved at least a 10% total body weight loss, a threshold often associated with clinically meaningful health benefits and reduced risk of comorbidities. Additionally, 62.5% of patients experienced improvements in at least one obesity-related comorbidity, such as a mean 5 mmHg reduction in systolic blood pressure or a 0.8% decrease in HbA1c (a measure of average blood sugar) in diabetic patients. The GLP-1 RAs were generally well-tolerated, with 25% of patients reporting mild gastrointestinal side effects (nausea, constipation) that resolved with dose adjustment or over time, and no serious adverse events were recorded.